Ample data indicate that mutant p53 proteins not only lose their tumour suppressive
functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies …

The partial cross-utilization of molecules and pathways involved in opposing processes like
cell survival, proliferation and cell death, assures that mutations within one signaling …

Spirulina is a well-described and popular dietary supplement derived from Arthrospira
algae. In the present study, the anticancer potential of a water extract of a commercial …

Introduction EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor
(TKI) treatment. Because co-occurring genomic alterations might describe different …

Prognosis of lung cancer still remains grim largely due to recurrence and aggressive
metastasis of the disease. In this study, we examined the potential of exosomal miRNAs as …

Background African-American breast cancer patients experience higher mortality rates than
European-American patients despite having a lower incidence of the disease. We tested the …

Lung cancer is the leading cause of cancer mortality worldwide. There have been only slight
improvements in early diagnosis and survival, reflecting limited advances in screening and …

Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer death in the
developed world. Platinum-based chemotherapy is the therapeutic foundation of treatment …

Purpose: TP53 mutations in early-stage non–small cell lung cancer (NSCLC) may be
associated with worse survival but their prognostic role in advanced NSCLC is controversial …

Background Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein
inhibiting proteolytic degradation of c-MYC. In this study, we investigated the clinical …